Literature DB >> 33085915

Obesity in Pulmonary Arterial Hypertension (PAH): The Pulmonary Hypertension Association Registry (PHAR).

Jeff Min1, Rui Feng2, David Badesch3, Erika Berman-Rosenzweig4, Charles Burger5, Murali Chakinala6, Teresa De Marco7, Jeremy Feldman8, Anna Hemnes9, Evelyn M Horn10, Matthew R Lammi11, Stephen Mathai12, John W McConnell13, Kenneth Presberg14, Jeffrey Robinson15, Jeffrey Sager16, Oksana A Shlobin17, Marc Simon18, Thenappan Thenappan19, Corey Ventetuolo20, Nadine Al-Naamani21.   

Abstract

RATIONALE: Obesity is associated with pulmonary arterial hypertension (PAH), but its impact on outcomes such as health-related quality of life (HRQoL), hospitalizations and survival is not well understood.
OBJECTIVES: To assess the effect of obesity on health-related quality of life (HRQoL), hospitalizations and survival in patients with PAH.
METHODS: We performed a cohort study of adults with PAH from the Pulmonary Hypertension Association Registry, a prospective multicenter registry. Multivariate linear mixed effects regression was used to examine the relationship between weight categories and HRQoL using the Short Form-12 (SF-12) and emPHasis-10 (e10). We used multivariable negative binomial regression to estimate hospitalization incidence rate ratios (IRRs) and Cox regression to estimate hazard ratios (HRs) for transplant-free survival by weight status.
RESULTS: 767 subjects were included: mean age of 57 years, 74% female, 33% overweight and 40% obese, with median follow-up duration of 527 days. Overweight and obese patients had higher baseline e10 scores (worse HRQoL), which persisted over time (p<0.001). The overweight and obese have a trend towards increased incidence of hospitalizations compared to normal weight (IRR 1.34, 95% confidence interval (95%CI) 0.94-1.92 and 1.33, 95%CI 0.93-1.89, respectively). Overweight and obese patients had lower risk of transplant or death as compared to normal weight patients (HR 0.45, 95%CI 0.25-0.80 and 0.39, 95%CI 0.22-0.70, respectively).
CONCLUSIONS: In a large multicenter, prospective cohort of PAH, overweight and obese patients had worse disease-specific HRQoL despite better transplant-free survival compared to normal weight patients. Future interventions should address the specific needs of these patients.

Entities:  

Year:  2020        PMID: 33085915      PMCID: PMC7869778          DOI: 10.1513/AnnalsATS.202006-612OC

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN: 2325-6621


  34 in total

1.  Five-Year outcomes of patients enrolled in the REVEAL Registry.

Authors:  Harrison W Farber; Dave P Miller; Abby D Poms; David B Badesch; Adaani E Frost; Erwan Muros-Le Rouzic; Alain J Romero; Wade W Benton; C Gregory Elliott; Michael D McGoon; Raymond L Benza
Journal:  Chest       Date:  2015-10       Impact factor: 9.410

2.  Association Between BMI and Obesity With Survival in Pulmonary Arterial Hypertension.

Authors:  Jason Weatherald; Alice Huertas; Athénaïs Boucly; Christophe Guignabert; Yu Taniguchi; Yochai Adir; Mitja Jevnikar; Laurent Savale; Xavier Jaïs; Mingkai Peng; Gérald Simonneau; David Montani; Marc Humbert; Olivier Sitbon
Journal:  Chest       Date:  2018-05-22       Impact factor: 9.410

3.  The relationship between obesity and mortality in patients with heart failure.

Authors:  T B Horwich; G C Fonarow; M A Hamilton; W R MacLellan; M A Woo; J H Tillisch
Journal:  J Am Coll Cardiol       Date:  2001-09       Impact factor: 24.094

4.  Relation Between Obesity and Survival in Patients Hospitalized for Pulmonary Arterial Hypertension (from a Nationwide Inpatient Sample Database 2003 to 2011).

Authors:  Manyoo Agarwal; Sahil Agrawal; Lohit Garg; Carl J Lavie
Journal:  Am J Cardiol       Date:  2017-05-11       Impact factor: 2.778

5.  Estimating a minimally important difference in pulmonary arterial hypertension following treatment with sildenafil.

Authors:  Claire Gilbert; Martin C J Brown; Joseph C Cappelleri; Martin Carlsson; Stephen P McKenna
Journal:  Chest       Date:  2008-09-23       Impact factor: 9.410

6.  Pulmonary and cardiovascular complications of obesity: an autopsy study of 76 obese subjects.

Authors:  Abida K Haque; Swarupa Gadre; Jerrod Taylor; Sajid A Haque; Daniel Freeman; Alex Duarte
Journal:  Arch Pathol Lab Med       Date:  2008-09       Impact factor: 5.534

7.  Initial Use of Ambrisentan plus Tadalafil in Pulmonary Arterial Hypertension.

Authors:  Nazzareno Galiè; Joan A Barberà; Adaani E Frost; Hossein-Ardeschir Ghofrani; Marius M Hoeper; Vallerie V McLaughlin; Andrew J Peacock; Gérald Simonneau; Jean-Luc Vachiery; Ekkehard Grünig; Ronald J Oudiz; Anton Vonk-Noordegraaf; R James White; Christiana Blair; Hunter Gillies; Karen L Miller; Julia H N Harris; Jonathan Langley; Lewis J Rubin
Journal:  N Engl J Med       Date:  2015-08-27       Impact factor: 91.245

8.  The association between obesity, mortality and filling pressures in pulmonary hypertension patients; the "obesity paradox".

Authors:  Barak Zafrir; Yochai Adir; Waseem Shehadeh; Michal Shteinberg; Nabia Salman; Offer Amir
Journal:  Respir Med       Date:  2012-11-28       Impact factor: 3.415

9.  Psychometric performance of the CAMPHOR and SF-36 in pulmonary hypertension.

Authors:  James Twiss; Stephen McKenna; Louise Ganderton; Sue Jenkins; Mitra Ben-L'amri; Kevin Gain; Robin Fowler; Eli Gabbay
Journal:  BMC Pulm Med       Date:  2013-07-12       Impact factor: 3.317

10.  emPHasis-10: development of a health-related quality of life measure in pulmonary hypertension.

Authors:  Janelle Yorke; Paul Corris; Sean Gaine; J Simon R Gibbs; David G Kiely; Carl Harries; Val Pollock; Iain Armstrong
Journal:  Eur Respir J       Date:  2013-11-14       Impact factor: 16.671

View more
  7 in total

1.  On errata and corrigenda-The Pulmonary Hypertension Association Registry (PHAR).

Authors:  Kayleen Williams; Noah A Kime; Richard A Kronmal; Nadine Al-Naamani
Journal:  Pulm Circ       Date:  2022-07-01       Impact factor: 2.886

2.  Erratum: Obesity in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.

Authors: 
Journal:  Ann Am Thorac Soc       Date:  2022-07

3.  Secular and Regional Trends among Pulmonary Arterial Hypertension Clinical Trial Participants.

Authors:  Jeff Min; Dina H Appleby; Robyn L McClelland; Jasleen Minhas; John H Holmes; Ryan J Urbanowicz; Steven C Pugliese; Jeremy A Mazurek; K Akaya Smith; Jason S Fritz; Harold I Palevsky; Jude Moutchia Suh; Nadine Al-Naamani; Steven M Kawut
Journal:  Ann Am Thorac Soc       Date:  2022-06

4.  The Association of Body Mass Index With Mortality Among Pulmonary Hypertension Patients: A Systematic Review and Meta-Analysis of Cohort Studies.

Authors:  Chaoxin Jiang; Xiongde Fang; Wenjin Fu
Journal:  Front Public Health       Date:  2022-05-10

5.  Mortality in Pulmonary Arterial Hypertension in the Modern Era: Early Insights From the Pulmonary Hypertension Association Registry.

Authors:  Kevin Y Chang; Sue Duval; David B Badesch; Todd M Bull; Murali M Chakinala; Teresa De Marco; Robert P Frantz; Anna Hemnes; Stephen C Mathai; Erika Berman Rosenzweig; John J Ryan; Thenappan Thenappan
Journal:  J Am Heart Assoc       Date:  2022-04-27       Impact factor: 6.106

6.  Endothelial senescence mediates hypoxia-induced vascular remodeling by modulating PDGFB expression.

Authors:  Priscilla Kyi; Kathryn Hendee; Tendai Hunyenyiwa; Kienna Matus; Tadanori Mammoto; Akiko Mammoto
Journal:  Front Med (Lausanne)       Date:  2022-09-20

7.  Erratum: Obesity in Pulmonary Arterial Hypertension: The Pulmonary Hypertension Association Registry.

Authors: 
Journal:  Ann Am Thorac Soc       Date:  2021-07
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.